You are here » Home » Companies » Company Overview » Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Ltd.

BSE: 540025 Sector: Industrials
NSE: ADVENZYMES ISIN Code: INE837H01020
BSE 00:00 | 24 Apr 2020 Advanced Enzyme Technologies Ltd
NSE 05:30 | 01 Jan 1970 Advanced Enzyme Technologies Ltd

Notice: Undefined property: stdClass::$market_capital_for_nse in /usr2/unibs/application/modules/live-market/views/scripts/company/bs-new-bse-nse-block.php on line 17
OPEN 147.30
PREVIOUS CLOSE 143.85
VOLUME 4459
52-Week high 225.00
52-Week low 91.05
P/E 30.68
Mkt Cap.(Rs cr) 1,569
Buy Price 140.00
Buy Qty 58.00
Sell Price 142.80
Sell Qty 50.00
OPEN 147.30
CLOSE 143.85
VOLUME 4459
52-Week high 225.00
52-Week low 91.05
P/E 30.68
Mkt Cap.(Rs cr) 1,569
Buy Price 140.00
Buy Qty 58.00
Sell Price 142.80
Sell Qty 50.00

Advanced Enzyme Technologies Ltd. (ADVENZYMES) - Chairman Speech


Notice: Undefined variable: pattern in /usr2/unibs/application/modules/live-market/views/scripts/company/annual-report.php on line 72

Company chairman speech

Dear Shareholders

On behalf of the Board of Directors and Management I am very pleasedto provide you all the annual performance report for the year 2018-2019. We have come along way from our roots pioneering the production of Papain in

1958. Since then there has been a global surge in demand for enzymesprobiotics and sustainable organic solutions driven by health awareness eco awarenessand increasing governmental regulation. Our high-value tailor-made solution modelcoupled with our true geographical diversity has placed us in a niche category. YourCompany is well-positioned to take advantage of the market trend.

We are proud to say that your Company's growth has been in linewith guidance. In FY19 our operating revenues grew by about 6% from 3957.0 million to4195.9 million our EBITDA grew by about 11% from 1639.6 to 1819.6 million and our PAT(before minority interest) has grown 24% from

935.6 million to 1159.0 million. As before the Human

Nutrition segment is our largest revenue driver (contributing

76% of revenue) followed by the Animal Nutrition segment (12% ofrevenue) and the Bio Processing segment (12% of revenue). On the Operations front ourcapacity utilization continues to be in the 52%-55% range.

In addition to making excellent progress in growing the size of ourbusiness we have also expanded our balance sheet maintained a tight rein on our debtand have a net cash surplus of about 994 million. We have made careful but developmentinvestments in the past significant and will continue to invest to do so. We firmlybelieve that research & development is the lifeline of your Company innovation isneeded for growth.

We are very proud of our substantial progress. The credit goes to thecommitted and hard-working employees of your

Company.

Through our decades of experience in this sector we believe the enzymeand probiotic industry is at a very exciting stage. We plan to leverage our brand andcontinue to explore new avenues for growth.

Thank you for being a part of our journey! We look forward to yourcontinued support.

With Best Regards

V. L. Rathi


Notice: Undefined variable: mediaAbsUrl in /usr2/unibs/application/modules/live-market/controllers/CompanyController.php on line 6077